Current and newer approaches in the drug treatment of congestive heart failure

Cardiovascular Drugs and Therapy

Volumn 10, Issue 6, 1997, Pages 693-702

  Van Zwieten, P A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Angiotensin II receptors; Beta adrenoceptors; Calcium antagonists; Congestive heart failure; Ibopamine; Neuroendocrine compensatory mechanisms; Vesnarinone

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM ANTAGONIST; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IBOPAMINE; PIPERANOMETOZINE; VASOPRESSIN ANTAGONIST;

CONGESTIVE HEART FAILURE; HUMAN; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; REVIEW;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOTONIC AGENTS; CHRONIC DISEASE; DIURETICS; HEART FAILURE, CONGESTIVE; HUMANS; RECEPTORS, ANGIOTENSIN;

EID: 0030996661     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00053026     Document Type: Review

References (70)

1. Packer M. The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-254.
2. Packer M. Pathophysiology of chronic heart failure. Lancet 1992;340:88-91.
3. Packer M. How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. Am J Cardiol 1993;71:3C-11C.
4. Van Zwieten PA, Lie KI. Neuroendocrine compensatory mechanisms as a target for the drug treatment of congestive heart failure. Cardiologie 1994;1:311-320.
5. Ritz E, Fliser D. The kidney in congestive heart failure. Eur Heart J 1991;12(Suppl C):14-20.
6. Packer M. Treatment of chronic heart failure. Lancet 1992; 340:92-95.
7. Van Zwieten PA. Neuroendocrine effects of diuretics in heart failure. Br Heart J 1994;72:51-53.
8. Van Zwieten PA. Changing insights in the drug treatment of congestive heart failure. Exp Opin Invest Drugs 1995; 17:186-190.
9. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neuro-humoral axis. Ann Intern Med 1985;103:1-6.
10. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: Clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987;57: 17-22.
11. Goldsmith SR, Francis G, Cohn JN. Attenuation of the pressor response to intravenous furosemide by angiotensin converting enzyme inhibition in congestive heart failure. Am J Cardiol 1989;64:382-385.
12. Alderman MH, Madhavan S, Oi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991;324:1098-1104.
13. Di Bianco R, Shabetai R, Kossuk W, Moran J, Schlant RC, Wright R. A comparison of oral milrinone, digoxin and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989;320:677-683.
14. Packer M, Gheorgiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. N Engl J Med 1993;329:1-7.
15. Van Zwieten PA. Receptor-mediated inotropic drugs. Eur Heart J 1988;9(Suppl H):85-90.
16. Pfeffer MA, Stevenson LW. β-Adrenergic blockers and survival in heart failure. New Engl J Med 1996;334:1396-1397.
17. Ferguson DW. Sympathetic mechanisms in heart failure. Patho-physiological and pharmacological implications. Circulation 1993;87(Suppl VII):68-75.
18. Van Veldhuisen DJ, Man in 't Veld AJ, Dunselman PHJM, et al. Double-blind, placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure. Results of the Dutch Ibopamine Multicentre Trial (DIMIT). J Am Coll Cardiol 1993;22:1564-1573.
19. Cohn JN, Archibald DG, Ziesche S, Franciosa J, Harston WE. Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Co-operative Study (V-HEFT). N Engl J Med 1986; 314:1547-1552.
20. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity and congestive heart failure: Relations to survival and the effects of therapy in V-HEFT II. Circulation 1993;87 (Suppl VI):40-48.
21. Cohn JN. The prevention of heart failure: A new agenda. N Engl J Med 1992;327:725-727.
22. Held P, Swedberg K. ACE-inhibitors in the treatment of heart failure. In Barnett DB, ed. Congestive Cardiac Failure. New York; Dekker 1993:169-183.
23. Packer M. Role of the sympathetic nervous system in chronic heart failure. Circulation 1990;82(Suppl 1):11-16.
24. Clissold SP, Brogden RN. Piretanide, a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1985;29:489-530.
25. Brater DC. Clinical pharmacology of loop diuretics. Drugs 1991;41(Suppl 3):14-22.
26. Lüllmann H. Digitalis glycosides: Drugs out of fashion. Progr Pharmacol 1990;7:1-7.
27. Van Zwieten PA. Cardiovascular drug therapy. What is new? ACE-inhibitors. Neth J Cardiol 1991;5:206-209.
28. Van Veldhuisen DJ. Ibopamine in Heart Failure. Efficacy and Safety in Clinical and Experimental Studies. Dissertation. Groningen: Rijksuniversiteit Groningen, 1993:20-29, 116-140.
29. Van Veldhuisen DJ, Crijns HJ, Girbes ARJ, Tobé JM, Wiesfeld ACF, Lie KI. Electrophysiologic profile of ibopamine in patients with congestive heart failure and ventricular tachycardia and relation to its effects on hemodynamics and plasma catecholamines. Am J Cardiol 1991;68: 1194-1202.
30. Girbes ARJ, Kalisvaart CJ, van Veldhuisen DJ, Smit AJ, Pasteuning WH. Effects of ibopamine on renal haemodynamics in patients with severe congestive heart failure. Eur Heart J 1993;14:279-283.
31. Dei Cas L, Metra M, Visioli O. Effects of acute and chronic ibopamine administration on resting and exercise hemodynamics, plasma catecholamines and functional capacity of patients with chronic congestive heart failure. Am J Cardiol 1993;70:629-634.
32. McMurray J, Cleland J, Cowley A. Ongoing and planned clinical trial in chronic heart failure and left ventricular dysfunction. Exp Opin Invest Drugs 1995;4:1069-1080.
33. Persson H, Erhardt L. Beta-receptor antagonists in the treatment of heart failure. Cardiovasc Drugs Ther 1991;5: 589-604.
34. Bristow MR, Hershberger RE, Port JD, et al. β-adrenergic pathways in non-failing human ventricular myocardium. Circulation 1990;82(Suppl 1):112-125.
35. Hjalmarson A, Waagstein F. The role of β-blockers in the treatment of cardiomyopathy and ischaemic heart failure. Drugs 1994;47(Suppl. 4):31-40.
36. Panfilow V, Wahlqvist I, Olsson G. Use of beta-adrenoceptor blockers in patients with congestive heart failure. Cardiovasc Drugs Ther 1995;9:273-287.
37. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-1446.
38. CIBIS Investigators and Committees. A randomised trial of beta-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1665-1673.
39. The BEST Steering Committee. Design of the Beta-blocker Evaluation Survival Trial (BEST). Am J Cardiol 1995;75: 1220-1223.
40. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995;92:212-218.
41. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-1506.
42. Heilbrunn SM, Shali P, Bristow MR, et al. Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 1989;79:483-490.
43. Packer M. Pathophysiological mechanisms underlying the effects of β-adrenergic agonists and antagonists on functional capacity and survival in chronic heart failure. Circulation 1990;82(Suppl 1):177-188.
44. Husain A. The chymase-angiotensin system in humans. Hypertension 1993;11:1155-1159.
45. Lacourcière Y, Brunner H, Irwin R, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994;12:1387-1393.
46. Crozier I, Ikram H, Awan N, et al. Losartan in heart failure. Hemodynamic effects and tolerability. Circulation 1995;91:691-697.
47. Pitt B, Chang P, Timmermans PBMWM. Angiotensin II-receptor antagonists in heart failure: Rationale and design of the Evaluation of Losartan in the Elderly (ELITE) Trial. Cardiovasc Drugs Ther 1995;9:693-700.
48. Raine A, Erne P, Burgisser E. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med 1986;315:533-537.
49. Eisner D, Müntze A, Kromer EP, Riegger AJ. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol 1992;70:494-498.
50. Münzel T, Kurz S, Holtz J, Busse R, Steinhauer H, Just H, Drexler H. Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure. Circulation 1992;86:1089-1098.
51. Reicher-Reiss H, Barasch E. Calcium antagonists in patients with heart failure. Drugs 1991;42:343-364.
52. Editorial. Meeting highlights. Circulation 1996;93:844-845.
53. Packer M. Presentation to the meeting of the European Society of Cardiology. Amsterdam, August 1995.
54. 3H]-des-methoxy-verapamil receptor, is devoid of the negative inotropic activity of verapamil in normal and failing rat hearts. Cardiovasc Drugs Ther 1990;4:731-736.
55. Portegiess MCM, Schmitt R, Kraaij CJ. Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris. J Cardiovasc Pharmacol 1991;18:746-751.
56. Creager MA, Faxon DP, Cutler SS, Kohlmann O, Ryan TJ, Gavras H. Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: Comparison with the renin-angiotensin system and the sympathetic nervous system. J Am Col Cardiol 1986;7:758-765.
57. Nicod P, Waeber B, Bussien JP, et al. Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. Am J Cardiol 1985;55: 1043-1047.
58. Mulinari RA, Gavras I, Wang YX, Kohlmann O, Gavras H. Effects of a vasopressin antagonist with combined antipressor and antidiuretic activities in rats with left ventricular dysfunction. Circulation 1990;81:308-311.
59. Van Meel JCA. Cardiovascular effects of the positive inotropic agents pimobendan and sulmazole in vivo. Arzneim Forsch 1985;35:284-288.
60. 2+-sensitivity of contractile proteins. Circulation 1986; 73(Suppl III):III78-III84.
61. Nankervis R, Lues I, Brown I. Calcium sensitization as a positive inotropic mechanism in diseased rat and human heart. J Cardiovasc Pharmacol 1994;24:612-617.
62. Remme WJ, Kruijssen DACM, van Hoogenhuyze X, Kraus H, Bartels CJ, Storm CJ, de Leeuw PW. Hemodynamic, neurohormonal, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure. J Cardiovasc Pharmacol 1994;24:730-739.
63. Remme WJ, Krayenbühl HP, Baumann G, Frick MH, Haehl M, Nehmiz G, Baiker W. Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind comparison with enalapril. Eur Heart J 1994;15: 947-956.
64. Hagemeijer F. Calcium sensitization with pimobendan: Pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. Eur Heart J 1993;14:551-566.
65. Yamashita S, Hosokawa T, Kojima M, Mori T, Yabuuchi Y. In vitro and in vivo studies of 3,4-dihydro-6[4-(3,4-dimethoxy-benzoyl)-1-piperazinyl]-2(1H)-quinolinone (OPC 8212), a novel positive inotropic drug in various animals. Arzneimittal forschung 1984;34:342-346.
66. Busch FW, Tillmann A, Becker EW, Owsianowski M, Berg PA. The inhibitory effects of a positive inotropic quinoline derivative, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-piperazinyl]-2(1H)-quinolinone (OPC 8212), on bone-marrow progenitor cells and peripheral lymphocytes. Eur J Clin Pharmacol 1992;42:629-633.
67. Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on mordibity and mortality in patients with heart failure. N Engl J Med 1993;329:149-155.
68. Packer M, Carver JR, Rodeheffer RJ, et al. For the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325:1468-1475.
69. Editorial. Xamoterol: Revised indications. Lancet 1990;335: 1394-1395.
70. Editorial. Flosequinan withdrawn. Lancet 1993;342:235.